| Cat. No. |
Product Name |
Information |
| PC-72640 |
SGC6870N
PRMT6 inhibitor
|
SGC6870N is the negative control of SGC-6870 (R-isomer), which is a potent, selective, cell-active PRMT6 inhibitor. |
| PC-72639 |
SGC6870
PRMT6 inhibitor
|
SGC6870 (SGC-6870 (R-isomer)) is a potent, selective, cell-active PRMT6 inhibitor with IC50 of 77 nM. |
| PC-72620 |
PF-06821497
EZH2 Y641N inhibitor
|
PF-06821497 (PF 06821497) is a potent, selective, orally bioavailable Enhancer of Zeste Homolog 2 (EZH2) inhibitor with Ki of <1 nM against Y641N mutant. |
| PC-72600 |
GSK3368715
Type I PRMT inhibitor
|
GSK3368715 (EPZ019997, GSK-3368715) is a potent, reversible and SAM uncompetitive type I PRMT inhibitor with Kiapp of 1.5 to 81 nM for PRMT1, 3, 4, 6, and 8. |
| PC-72513 |
PF-06939999
PRMT5 inhibitor
|
PF-06939999 (PF06939999) is a potent, selective, S-adenosylmethionine (SAM) competitive PRMT5 inhibitor with SPR Kd of 5.8 pM. |
| PC-72495 |
BRD0639
PRMT5 inhibitor
|
BRD0639 (BRD-0639) is a first-in-class, specific inhibitor of interaction between PRMT5 and its substrate adaptor protein (PRMT5 binding motif) with IC50 of 13.8 uM. |
| PC-72494 |
ASH1L inhibitor AS-99
ASH1L inhibitor
|
ASH1L inhibitor AS-99 (AS-99) is a first-in-class, potent, selective inhibitor of ASH1L histone methyltransferase with IC50 of 0.79 uM. |
| PC-72488 |
EEDi-5285
PRC2 EED inhibitor
|
EEDi-5285 (EEDi5285) is a highly potent, efficacious, and orally active EED inhibitor with IC50 of 0.2 nM. |
| PC-72471 |
MS4322
PRMT5 degrader
|
MS4322 (MS-4322) is a potent, highly selective PRMT5 degrader (PROTAC) by linking the PRMT5 inhibitor EPZ015666 to a von Hippel-Lindau (VHL) E3 ligase ligand, with PRMT5 protein DC50 of 1.1 uM in MCF-7 cells. |
| PC-72468 |
AH237
PRMT4/5 inhibitor
|
AH237 (AH-237) is a potent and selective inhibitor for PRMT4 and PRMT5 with IC50 of 2.8 and 0.42 nM, respectively. |
| PC-72444 |
JNJ-64619178
PRMT5 inhibitor
|
JNJ-64619178 (Onametostat, JNJ 64619178) is a selective, and potent PRMT5 inhibitor with Kiapp of 0.77 nM, inhibits the PRMT5/MEP50 complex impairing cancer cell proliferation. |
| PC-72438 |
KO-539
menin-MLL inhibitor
|
KO-539 (Ziftomenib, KO 539) is a potent and selective menin-MLL inhibitor under clinical investigation for treatment of acute myeloid leukemia (AML). |
